Table 1. Studies of BV and PD-1 blockade... | American Society of Hematology

Table 1.

Studies of BV and PD-1 blockade in multiply relapsed/refractory cHL

Regimen	Phase	N	ORR (%)	CRR (%)	NCT no.	Reference
BV monotherapy and combination therapy in R/R cHL
BV	2	102	75	34	NCT00848926	13
BV-ibrutinib	2	39	69	46	NCT02744612	28
BV-bendamustine	1/2	64	71	32	NCT01657331	29
BV-ipilimumab	1	21	76	57	NCT01896999	30
BV-nivolumab	1	18	88	61	NCT01896999	30
BV-nivolumab-ipilimumab	1	22	82	73	NCT01896999	30
Anti PD-1 monotherapy and combination therapy in R/R cHL
Nivolumab	2	243	69	16	NCT02181738	16
Pembrolizumab	2	210	69	22	NCT02453594	18
Nivolumab+ipilimumab	1b	31	74	23	NCT01592370	31
Pembrolizumab+vorinostat	1	9*	100	44	NCT03150329	32
Camrelizumab+decitabine	2				NCT03250962	33
Anti-PD-1 naive	—	42	95	71	—
Prior anti-PD-1	—	25	52	28	—

Regimen	Phase	N	ORR (%)	CRR (%)	NCT no.	Reference
BV monotherapy and combination therapy in R/R cHL
BV	2	102	75	34	NCT00848926	13
BV-ibrutinib	2	39	69	46	NCT02744612	28
BV-bendamustine	1/2	64	71	32	NCT01657331	29
BV-ipilimumab	1	21	76	57	NCT01896999	30
BV-nivolumab	1	18	88	61	NCT01896999	30
BV-nivolumab-ipilimumab	1	22	82	73	NCT01896999	30
Anti PD-1 monotherapy and combination therapy in R/R cHL
Nivolumab	2	243	69	16	NCT02181738	16
Pembrolizumab	2	210	69	22	NCT02453594	18
Nivolumab+ipilimumab	1b	31	74	23	NCT01592370	31
Pembrolizumab+vorinostat	1	9*	100	44	NCT03150329	32
Camrelizumab+decitabine	2				NCT03250962	33
Anti-PD-1 naive	—	42	95	71	—
Prior anti-PD-1	—	25	52	28	—

CRR, complete response rate.

Includes patients with both prior PD-1 blockade and PD-1 refractory.